Disconnected workflow
Diagnosis and treatment often occur in separate steps, across different settings and timelines.
Intelligent skin cancer surgery
Single procedure theranostics
EpiMass enables seamless diagnosis and treatment of skin cancer in a single procedure, reducing fragmentation in clinical workflows and improving patient outcomes.
Experience surgical guidance with EpiMass!
Hover to classify tissue. Click, hold, and drag to ablate the tumor only.
Live spectral readout
Mode
Scanning
ClassificationBackground
Illustration for demonstration purposes only. Not representative of validated clinical data
Unmet need
Skin cancer care remains fragmented across diagnosis and treatment
For many patients, the path from suspicion to confirmed diagnosis and appropriate treatment involves multiple appointments, delays, and handoffs between specialties. This fragmentation can prolong uncertainty, increase healthcare burden, and complicate timely intervention.
Prolonged uncertainty
Patients may wait between biopsy, histopathology, and treatment planning — a period of significant anxiety.
System-level burden
Repeated visits and fragmented pathways place additional demand on clinicians and healthcare systems.
The EpiMass approach
An integrated concept for diagnosis and treatment in one procedure
EpiMass is developing a technology intended to support clinicians in evaluating suspicious lesions and proceeding toward treatment within a more unified clinical workflow. The approach is designed with the goal of reducing procedural fragmentation while maintaining rigorous clinical standards.
Workflow integration
Designed to bring diagnostic evaluation and treatment planning closer together within a single clinical encounter.
Clinician-centered design
Developed with input from clinical practice needs, prioritizing usability within existing dermatological workflows.
Evidence-driven development
Progressing through structured pre-clinical and clinical evaluation to generate supporting evidence.
EpiMass is in early development. The described capabilities represent development objectives and are subject to clinical validation and regulatory review.
Team
Experienced leadership building toward clinical impact
EpiMass brings together clinicians, analytical scientists, and mass spectrometry pioneers from leading institutions in Denmark, the UK, and Germany.
Dr. Lauritz Brorsen
CEO & Founder
Dr. Lauritz Brorsen is a postdoctoral researcher at Bispebjerg Hospital and the University of Copenhagen, where he combines mass spectrometry, machine learning, and laser technology to advance real-time skin cancer diagnostics and treatment. As founder and CEO of EpiMass, he leads the translation of this research toward integrated surgical guidance for keratinocyte carcinoma.
LinkedIn
Prof. Zoltan Takats
Distinguished Scientific Advisor
Professor Zoltan Takats is a pioneer of ambient mass spectrometry and primary inventor of techniques including REIMS and the intelligent surgical knife (iKnife) at Imperial College London. He also holds an affiliation with the University Hospital Regensburg, where his group develops mass spectrometry tools for real-time tissue analysis and surgical guidance.
LinkedIn
Assoc. Prof. Catharina Lerche
Scientific Coordinator
Associate Professor Catharina Lerche bridges clinical dermatology at Bispebjerg Hospital with pharmaceutical sciences at the University of Copenhagen. Her research focuses on mass spectrometry-based methods for skin cancer diagnostics, DNA damage quantification, and photocarcinogenesis.
LinkedIn
Dr. Daniel Simon
Scientific Advisor
Dr. Daniel Simon is a research associate in the Department of Metabolism, Digestion and Reproduction at Imperial College London, specializing in ambient and laser-based mass spectrometry. He develops REIMS and LD-REIMS platforms for tissue imaging, molecular pathology, and integration with surgical instrumentation, in collaboration with the University Hospital Regensburg.
Prof. Merete Hædersdal
Clinical Advisor
Professor Merete Hædersdal is Director and Head of Research at the Danish Research Center for Skin Cancer and a consultant dermatologist at Bispebjerg Hospital. Her translational research focuses on laser and energy-based treatments for skin cancer and premalignant lesions, with extensive experience leading clinical research programmes.
LinkedIn
Prof. Peter Bjerring
Clinical Advisor
Professor Peter Bjerring is a clinical professor and consultant dermatologist at Aalborg University Hospital and Privathospitalet Mølholm. With more than three decades of experience in laser and light-based dermatology, he has helped establish the Danish Research Center for Skin Cancer and advance non-invasive skin cancer treatment.
LinkedIn
Dr. Jonatan Granborg
Scientific Advisor
Dr. Jonatan Riber Granborg is a pharmacist and postdoctoral researcher at Bispebjerg Hospital and the Danish Research Center for Skin Cancer. He develops LC-MS and mass spectrometry methods to quantify DNA damage biomarkers and support analytical chemistry in skin cancer research.
LinkedIn
Assoc. Prof. Christian Janfelt
Scientific Advisor
Associate Professor Christian Janfelt leads research in drug toxicology, metabolism, and mass spectrometry imaging at the University of Copenhagen's Department of Pharmacy. He develops and applies DESI-MSI and MALDI-MSI techniques for pharmaceutical analysis and biological imaging, including collaborations on skin cancer mass spectrometry projects.
LinkedInFAQ
Frequently asked questions
EpiMass is in early development. The company has progressed through initial concept and prototype stages and is now initiating pre-clinical evaluation and clinical implementation studies.
Clinical validation is underway as part of our structured development pathway. No clinical outcomes are reported publicly at this stage. Results will be shared as studies progress and data become available.
EpiMass is engaging with regulatory frameworks appropriate to its intended classification and markets. Specific regulatory milestones and submissions will be communicated as the pathway advances.
We welcome engagement from clinical investigators, healthcare institutions, strategic partners, and investors who share our commitment to advancing skin cancer care through evidence-based innovation.
No. EpiMass is not commercially available and is not approved for clinical use. The technology is in development and subject to clinical evaluation and regulatory review.
Please reach out via the email address in our contact section or footer. We respond to inquiries from investors, clinical partners, and collaborators.
Contact
Let's advance skin cancer care together
Whether you are an investor, clinical partner, or collaborator, we welcome the opportunity to discuss how EpiMass can contribute to better patient outcomes.
Get in touch at
contact@epimass.com